ClinicalTrials.gg
RecruitingNCT05982769Updated Sep 28, 2026

Molecular Mechanism of Exercise in Cirrhosis

An interventional study of Endurance Training 3 times per week and Resistance Exercise in Cirrhosis, Liver, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 231 studies in Liver Cirrhosis with a site in United States — 45 open to participants now, 63 under way, 3 of them phase 3. Liver Cirrhosis · United States.

Planned enrollment
95th of 166
40 · median 55
Started
2023
with 15 others
No phase
50 of 231
11 open now
Primary completion
2027-08
later than 30 of 62 live
Registered
191st of 231
by date

Among the 231 studies in Liver Cirrhosis with a site in United States, this one is the 95th largest by planned enrollment of the 166 interventional ones that give a count, is one of 16 that started in 2023, is one of 50 with no phase, reaches primary completion later than 30 of the 62 other live ones, and was the 191st registered.

Liver Cirrhosis

1,302 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

45 of the 231 studies in Liver Cirrhosis with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 207 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 65 (31%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies in Liver Cirrhosis with a site in United States, or all of them as a file.
02

Study summary

This study aims to investigate the effects of 12 weeks of resistance or endurance exercise on patients with cirrhosis. Cirrhotic patients are prone to muscle loss (sarcopenia) and ammonia build up due to liver dysfunction. The liver which in healthy patients is able to process ammonia through ureagenesis is unable to do so in cirrhosis and ammonia is taken up either by the brain causing confusion or the skeletal muscle causing muscle loss or sarcopenia. Primary sarcopenia occurs in older individuals and can be mitigated by exercise. Secondary sarcopenia occurs in response to disease such as cancer, chronic kidney disease, multiple sclerosis, and cirrhosis of all etiologies. Resistance exercise is an excellent stimulator for muscle protein synthesis and is widely used to build muscle mass and strength but has little benefit to cardiovascular function. Endurance exercise has shown to be safe in cirrhosis however there is no set prescription for cirrhosis as there is for other disease. Endurance exercise is known to promote improved cardiovascular health, improve fatigue, and generates less ammonia build up than resistance exercise. In patients with low muscle mass it is possible that endurance exercise alone will be enough to improve muscle mass. There have been few studies on exercise and cirrhosis, those that exist have shown benefits with endurance exercise. However there are even more limited studies on resistance exercise and few to no studies on the molecular mechanisms behind exercise in cirrhosis. Study visits are described fully in the protocol and consent form. After passing a screening visit patients will undergo a maximal exercise/fitness test (pre-baseline test) and other body composition measurements. After the screening and pre-baseline visit randomization will occur (2:2:1 endurance, resistance, or SOC) arrangements will be made to have the appropriate exercise equipment given to patients. Once the exercise equipment has arrived a baseline study visit will occur. After the baseline visit the endurance exercise group will cycle 3 days per week for 60 minutes under the supervision of the study team. The resistance exercise group will perform a whole body resistance workout 2 days per week for approximately 60 minutes under the supervision of a study team member.

Patients in all groups will have the fitness test repeated at weeks 4, 8 and 12. After the 12 weeks of exercise the baseline visits will be repeated and after 2 weeks patients will complete one final fitness test to examine the effects of de-training.

03

Conditions studied

  • Cirrhosis, Liver

Browse trials for

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion

  • Adult patients age 21-65 years of both genders
  • Diagnosis of cirrhosis by either liver , clinical, biochemical or imaging criteria
  • Child's score 5-10
  • Model for End Stage Liver Disease (MELD) score less than 21
  • Abstinence from alcohol and/or other recreational drugs for at least 6 months
  • Absence of concurrent illnesses (renal, cardiac, pulmonary, cerebrovascular, ) or medication (anabolic steroids, ) intake that affect skeletal muscle mass, diabetes mellitus (avoid altered muscle protein metabolism), or use of anticoagulants.
  • abdominal or liver CT scan within 1 year of enrollment for stratification Exclusion
  • Active alcohol consumption within 6 weeks of enrollment
  • Pedal edema (grade 2) above the ankle will be excluded to avoid complications of the muscle biopsy.
  • Liver transplant
  • Active Malignancy
  • Recent GI bleed (4 weeks)
  • Hepatic Encephalopathy within previous 6 months
  • Grade 2 or greater active esophageal varices
  • Active infection
  • Large Ascites as defined by clinical imaging
  • Advanced disease cardiac or pulmonary disease
  • Use of medications affecting muscle protein turnover including corticosteroids or medications used to prevent clotting
  • Clinical lab values that indicate potential poor clotting as determined by the PI
  • Inability to obtain ; judged likely to be unable to perform exercise or unlikely to complete the study in the opinion of the investigators
  • End stage kidney disease as determined by (eGFR) \< 15 ml/min/1.73m2 or dialysis
  • Patients who in the opinion of the PI are unsafe for exercise (failure to pass stress test)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Endurance Arm

    Behavioral: Endurance Training 3 times per week

  • Experimental
    Resistance

    Behavioral: Resistance Exercise

  • Active comparator
    Standard of Care

    Behavioral: Standard of Care

Interventions

  • BehavioralEndurance Training 3 times per week

    endurance training will be performed from home 3 times per week under the supervision of the research team.

  • BehavioralResistance Exercise

    resistance training will be performed from home 2 times per week under the supervision of the research team.

  • BehavioralStandard of Care

    continue usual activity

06

What researchers measure

Primary outcomes

  1. Change in muscle mass over time

    Time frame: day 0 and day 90

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Aug 2027, 50 months after the start.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 50 months is above that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2023
First posted
Aug 9, 2023
StartActual
Jun 1, 2023
Primary completionEst.
Aug 10, 2027
CompletionEst.
Aug 10, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05982769
Responsible party
Srinivasan Dasarathy (Staff Physician, The Cleveland Clinic) — Principal investigator
First posted
Aug 9, 2023
Start date
Jun 1, 2023
Primary completion
Aug 10, 2027 (estimated)
Completion
Aug 10, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Srinivasan Dasarathy, MD
Contact
dasaras@ccf.org
216-318-7010
Annette Bellar
Contact
bellara@ccf.org

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion